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Summary: In order to compare the value of different leads and lead combinations to 
detect the signature Brugada type ECG pattern, we analysed digital 10-second, 15-lead 
ECGs (12 standard leads + leads V1 to V3 from 3
rd intercostal (i.c.) space, V1h to V3h) 
acquired during diagnostic Ajmaline testing in 128 patients (80 men, age 37±15 years) with 
suspected Brugada syndrome (BS) (patient group), 15-lead resting ECGs of 108 healthy 
subjects (53 men, age 31.9±10.5 years) (control group A) and standard 12-lead resting ECGs 
of 229 healthy subjects (111 men, age 33±4 years) (control group B). Bipolar leads between 
V2 (positive pole) and V4 or V5 (leads V2-4, V2-5) were derived by subtracting leads V4 and V5 
from V2 (custom-made program). The 6 peripheral, 6 right precordial leads (V1 to V3, V1h to 
V3h) and leads V2-4 and V2-5 of the patients group, leads V1h to V3h of control group A, and 
leads V2-4 and V2-5 of control group B were analysed for the presence of type 1 Brugada pattern. 
There were 21 (16.4%) positive and 107 (83.6%) negative Ajmaline tests. In 7 positive 
tests (33%), type 1 pattern appeared only in leads V1h to V3h, whereas in 14 tests 
67%) it appeared in both V1 to V3 and V1h to V3h. Lead V2 displayed type 1 pattern 
during 10 positive tests; in all of them, plus 10 other positive tests type 1 was also 
noted in lead V2h (n=20, 95.2%).  In all 10 cases, in which lead V2 exhibited type 1 pattern 
(n=10), lead V2-4 and/or V2-5 also exhibited type 1-like pattern. During 7 positive tests, in which 
lead V2h but not V2 exhibited type 1 pattern, lead V2-4 and/or V2-5 also demonstrated type 1 
pattern. Type 1 pattern was observed in leads V3 and V3h during 1 (5%) and 5 (24%) positive 
tests, in 0 ECGs (0%) in control group A and in 1 ECG (0.4%) in control group B. In 
conclusion, the “high” V1 and V2 leads (3
rd i.c. space) detect more sensitively Brugada type 1 
pattern than the standard V1 and V2 leads (4
th i.c. space); leads V3 and V3h are not essential 
for the diagnosis of BS; bipolar leads V2-4 and V2-5 are superior to lead V2 for the ECG 
diagnosis of BS. 
 
Keywords: Brugada syndrome, Ajmaline test, High right precordial leads, Bipolar 
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1. INTRODUCTION 
 
The Brugada Syndrome (BS) is an inherited arrhythmia syndrome 
manifesting as syncope or sudden cardiac death (SCD) due to a 
polymorphic ventricular tachycardia in the absence of myocardial 
ischemia, structural heart disease or QT prolongation [4]. Currently 
the BS is diagnosed when a specific electrocardiographic (ECG) 
pattern characterized by J-point and ST-segment elevation with 
negative T wave (“coved” or type 1 Brugada ECG pattern) (Fig.1) is 
observed in the right precordial leads V1 
to V3 in patients with personal or family 
history of major ventricular arrhythmic 
events and/or blood relatives carrying the 
type 1 ECG [2].  
 
In patients with normal or non-diagnost-
ically changed baseline ECG, the signature 
type 1 Brugada ECG pattern can be 
provoked by intravenous administration of 
drugs which block the sodium channel 
(Ajmaline, flecainide, procainamide) [2, 
21]. However, it is still not clear which are 
the best ECG leads or lead combinations 
to be monitored during the test (and for 
detection of Brugada ECG pattern in 
general). Recent studies [16, 20] have 
demonstrated that recording leads V1 and 
V2 from the 3
rd or 2
nd instead of the 4
th 
intercostal (i.c.) space would increase their 
sensitivity for detection of type 1 Brugada 
pattern. However, the “high” right precordial leads should preferably 
be recorded in addition to, and not instead of the standard V1 to V3 
leads because the latter are essential for the general interpretation of 
the ECG. Unfortunately, ECG recorders capable of simultaneous 
acquisition of more than 12 leads are not always available. 
Fig. 1 Typical type 1 
(coved) Brugada ECG 
attern observed in lead V1
corded from the standar
osition in 4
p  
re d 
p
A
mm V. 
th intercostal 
(i.c.) space (top) and from 
the 3
rd i.c. space (bottom). 
ll ECGs in Figures 1 to 5 
are presented at 25 
/second, 1 cm/m
 
In order to assess the value of different leads and lead combinations 
for detection of the signature type 1 Brugada ECG pattern, we 
retrospectively analyzed a database of 15-lead digital ECG 
recordings acquired during diagnostic Ajmaline testing in patients 
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with suspected BS, and a database of 12- and 15-lead digital resting 
ECGs recorded in subjects with no apparent heart disease. 
 
2. METHODS 
 
Patient population and ECG data acquisition 
Between August 2006 and February 2009, diagnostic Ajmaline test 
was performed in 128 patients (80 men, 48 women, age 37.0±15.1 
and 38.9±14.8 years, respectively, p=0.48), with suspected BS as 
part of their standard clinical management. Indications for the test 
included: a) aborted cardiac arrest (n=12), b) syncope of unknown 
origin (n=34), c) family history of BS (n=35) or sudden cardiac 
death (SCD) (n=53) and d) ECG changes suspicious for but not 
diagnostic of BS (n=6) (more than one indication was present in 
some patients). Ajmaline was administered intravenously in dose 1 
mg/kg for 5 minutes under constant ECG monitoring in hospital 
setting [2].  
 
Digital 10-second ECGs with simultaneous acquisition of 15 leads 
(standard 12-leads plus leads V1 and V2 from the 3
rd i.c. space, and lead 
V3 with the same cranial displacement – high V1 to V3 leads, V1h to 
V3h) were acquired before, at short intervals (3 – 5 ECGs per minute) 
during and up to 10 minutes after the end of drug infusion or until the 
ECG changes completely subsided using MAC 5000 recorder (GE 
Medical, Milwaukee, WI, USA, 500 Hz, 4.88 µV). All ECGs were 
subsequently converted into XML text files to be analyzed with a custom-
developed program (see below). For the purpose of this study, a test was 
considered positive if any two (or more) of the 6 leads (V1 to V3 plus V1h 
to V3h) demonstrated type 1 ECG pattern during the test, although the 
inclusion of the high right precordial leads in the definition of a positive 
test is not clearly endorsed by the Consensus Documents [2].
 
Healthy controls 
We also analyzed digital 10-second ECGs (MAC5000, MAC55000 or 
CardioSoft, GE Medical 500 Hz, 4.88 µV) recorded in 2 groups of healthy 
subjects participating in different research projects approved by the local 
Ethics Committee: 
•  15-lead digital ECGs acquired in 108 subjects (53 men, age 
31.9±10.5 years) with the same lead configuration as in the 
patient group (control group A). They were used to assess the 
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presence of type 1 Brugada ECG pattern in leads V1h to V3h in 
healthy subjects. 
•  Standard 12-lead ECG recorded in 229 subjects (111 men, age 
33.4±10.6 years) (control group B). They were used for analysis 
of the bipolar leads V2-4 and V2-5 (see below) in healthy subjects. 
All subjects in both groups had negative personal and family medical 
history, normal physical examination and normal standard 12-lead resting 
ECG. 
 
Derivation of bipolar precordial leads 
We hypothesized that a bipolar precordial lead with a positive electrode 
overlying a myocardial zone with expected electrophysiological changes 
in BS (e.g. at V2 position) and a negative electrode above a supposedly 
healthy myocardium (e.g. at V4 or V5) could detect more sensitively the 
diagnostic type 1 Brugada pattern than the standard unipolar lead with the 
same positive pole (lead V2). Bipolar precordial leads can be recorded 
directly – for example, when the right arm and left arm cables are 
connected to the V4 and V2 electrodes, respectively, lead I displays a 
bipolar lead between V2 (positive pole) and V4 (negative pole). Bipolar 
recordings, however, can be obtained more easily by subtracting the 
respective unipolar leads. For example, lead V2 = EV2 – EWCT, where EV2 is 
the potential at V2 and EWCT is the potential of Wilson’s central terminal 
(the average potential of the right arm, left arm and left leg). Similarly, 
lead V4 = EV4 – EWCT. Therefore, V2 – V4 = EV2 – EV4, i.e. subtracting 
lead V4 from lead V2 is equivalent to recording a bipolar lead with 
electrodes at V2 (positive pole) and V4 (negative pole).  
 
We used a custom developed program to obtain bipolar leads between V2 
(positive pole) and V4 or V5 (lead V2-4  and V2-5, respectively) by 
subtracting V4 and V5, respectively, from V2. We chose lead V2 instead 
of V1 or V3 because, firstly, Brugada type changes are observed much 
more frequently in leads V1 or V2 that in lead V3 (unpublished 
observations) and, secondly, because preliminary observations suggested 
that the shape of the QRS-T wave of bipolar lead V1-4 and V1-5 is more 
variable and hence more difficult to interpret than that of leads V2-4 or V2-5.  
 
Data analysis 
For each Ajmaline test, we analyzed two 10-second ECGs recorded 
immediately before the beginning of Ajmaline infusion, and during each 
minute from the 1
st to the 7
th, 10
th and 15
th after drug infusion was started 
(20 ECGs per test) excluding those with visibly high noise and 
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arrhythmias. In the patient group, the presence or absence of Brugada type 
1 pattern [2, 4]
 was noted in each of the 6 peripheral, 6 unipolar precordial 
(V1 to V3, V1h to V3h) and 2 derived bipolar leads (V2-4 and V2-5). In the 
following text, however, Brugada type 1 pattern in leads V2-4 and V2-5 is 
referred to as “type 1-like pattern” since its origin in these leads is not 
clear. The prognostic value of different leads or lead combinations can 
only be established in relation to the occurrence of symptoms and/or 
arrhythmic events during follow-up. Such data were not available in the 
present study. Therefore we calculated the value of different lead 
combinations for detecting a positive test defined as type 1 pattern in any 2 
of the 6 unipolar leads V1 to V3 plus V1h to V3h and their sensitivity to 
detect BS defined as a positive test plus relevant family history and/or 
relevant symptoms [2].
 
Leads V1h to V3h of all ECGs in all subjects of control group A, and the 
derived bipolar leads V2-4 and V2-5 in control group B were also examined 
for the presence or absence of Brugada type 1 ECG pattern.  The standard 
12-leads in all subjects in the 2 control groups were by definition normal. 
 
Data are presented as mean ± standard deviation. Nominal and categorical 
values were compared between study groups using paired and unpaired 
two-tailed student t-test and chi-square test, respectively. A two-tailed P-
value of < 0.05 was considered statistically significant. 
 
3. RESULTS 
 
Out of 128 Ajmaline tests, 21 (16.4%) were positive and 107 (83.6%) 
were negative. Of those with positive tests, 18 (85.7%) were subsequently 
diagnosed as having BS due to family history of BS (n=9), aborted cardiac 
arrest (n=2), unexplained syncope (n=3), family history of SCD either 
alone (n=2) or in combination with syncope (n=1) or with family history 
of BS in a different family member (n=1) [2]. Three asymptomatic 
patients with positive tests and negative family history who were 
investigated because of the presence of ECG changes suggestive but not 
diagnostic of BS were considered to be asymptomatic carriers of Brugada 
type ECG [2, 3]. 
 
Comparison between the standard (V1 to V3) and high (V1h to V3h) 
right precordial leads 
In accordance with previous reports, type 1 Brugada pattern was observed 
more frequently in leads V1h to V3h than in the standard V1 to V3 leads. 
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In 7 out of 21 (33%) positive tests, type 1 ECG pattern developed only in 
leads V1h to V3h leads, whereas in the rest (n=14, 67%) it was noted in 
both standard and high right precordial leads. Lead V2 displayed type 1 
pattern during 10 out of 21 positive tests (47.6%). In these tests, plus in 10 
other positive tests, type 1 was noted in lead V2h (20 out of 21, 95.2%). 
Type 1 pattern was observed in leads V3 and V3h during 1 (4.8%) and 5 
(23.8%) positive tests, respectively. In none of the positive tests were leads 
V3 or V3h essential for the diagnosis (i.e. in each test, in which either lead 
V3 or V3h displayed type 1 Brugada pattern, at least 2 other of the 6 right 
precordial leads also displayed this pattern). 
 
Brugada type 1 ECG pattern was not observed in leads V1h to V3h of any 
subject from control group A. 
 
Comparison between leads V2, V2h and the bipolar leads V2-4/V2-5 
In all ten cases, in which lead V2 exhibited type 1 pattern (n=10), lead V2-4 
and/or V2-5 also exhibited type 1-like pattern. However, during 7 positive 
tests, in which the high V2 lead (V2h) exhibited type 1 pattern whereas 
lead V2 showed only non-diagnostic changes, either one or both of leads 
V2-4 and V2-5 also demonstrated Brugada type 1-like pattern.  
 
Table 1. Value of different lead combinations for detection of BS and of 
asymptomatic carriers of Brugada ECG pattern 
Leads 
Number (%) of 
all positive tests 
(n=21)* 
Number (%) of 
patients with 
BS (n=18)‡ 
Number (%) of 
carriers of Brugada 
ECG pattern (n=3)§ 
V1,V2,V3  7 (33.3%)  6 (33.3%)  1 (33.3%) 
V1h,V2h,V3h  19 (90.5%)  16 (88.9%)  3 (100%) 
V1,V2-4, V2-5,V3  9 (42.9%) †  8 (44.4%)  1 (33.3%) 
*  number (%) of all positive tests, in which ≥ 2 leads of the combination 
showed Brugada type 1 or type 1-like pattern;  
†  either one or both of leads V2-4 and V2-5 showed Brugada type 1-like pattern; 
‡  number (%) of patients with positive tests who subsequently were diagnosed 
with Brugada syndrome according to the accepted criteria;  
BS  Brugada syndrome;  
§  asymptomatic patients with positive tests who do not fulfil the criteria for BS 
 
Table 1 presents the value of 3 different combinations of leads (V1 to V3, 
V1h to V3h, and V1, V2-4/V2-5, V3) for detection a positive test (i.e. the 
number/percentage of positive tests, in which each of these combinations 
displayed type 1 or type 1-like pattern in ≥2 leads), and for detection of BS 
(i.e. positive test plus relevant family history and/or relevant symptoms or 
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arrhythmic events). Substituting lead V2 with the bipolar leads V2-4/V2-5 
would increase the ability of the standard precordial leads to detect a 
positive test from 33.3% (7/21) to 42.9% (9/21), and to detect BS from 
33.3% (6/18) to 44.4% (8/18). 
 
Figures 2 to 4 present examples of ECGs recorded before and after admin-
istration of Ajmaline during positive tests to demonstrate the increased 
sensitivity of the bipolar leads V2-4 and V2-5 compared to that of the 
standard unipolar lead V2 for detection of type 1 Brugada pattern. 
 
 
Fig. 2 ECGs recorded before (left panel) 
and 6’40’’ after the start of Ajmaline 
infusion (right panel) during a positive test 
in a 34-year-old man with a history of 
syncope. Note that 6’ 40’’ after the start of 
drug infusion leads V2-4 and V2-5 display a 
clear type 1-like pattern whereas lead V2 
shows a non-diagnostic type 2 pattern 
(right panel). In the absence of high leads 
the test would have been interpreted as 
non-positive (type 1 pattern in leads V1, 
V1h and V2h). All ECGs on Figures 1 to 5 
are presented at 25 mm/sec and 10 
mm/mV. 
 
 
 
 
Leads V2-4 and V2-5 during non-positive Ajmaline tests and in healthy 
controls 
Type 1-like pattern was observed in lead V2-4 and V2-5 in 2 patients during 
non-positive tests (false-positive results). However, the first patient 
probably had atypical (inferior) type BS (appearance of type 1 developed 
in III and AVF during the test), whereas in the second patient the result of 
the test was borderline (coved type ST elevation with J point elevation of 
slightly less than < 2 mm in leads V1, V1h and V2h).  
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Fig. 3 ECGs acquired before (left 
panel), 3’ (middle panel) and 6’ 
(right panel) after the beginning of 
Ajmaline infusion in a 15-year-old 
girl with a syncope and family 
history of BS. Note that type 1 
Brugada-like pattern appears earlier 
in leads V2-4 and V2-5 than in leads 
V2 and V2h (middle panel). 
 
Fig. 4 ECGs recorded before (left 
panel) and 3’50’’ after the 
beginning of Ajmaline test (right 
panel) in a 44 year old asympto-
matic woman who had several 
family members diagnosed with 
BS. Note that lead V2 displays 
borderline changes during the test 
(J elevation < 2 mm) whereas 
lead V2-4 displays typical type 1-
like pattern (right panel). 
 
ECG changes only to some extent resembling Brugada type 1 pattern were 
observed in only one 24-year-old healthy man of control group B (0.4%) 
(Fig. 5). 
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Fig. 5 Lead V2-4 (left 
panel) and V2-5 (right 
panel) derived from a 
resting ECG of 24-year-
old healthy man (thick 
black lines). For compar-
ison, the average complex 
(thin black line) and 
standard deviation (grey 
zone) of all positive tests 
in which V2-4 (left panel) 
or V2-5 (right panel) 
displayed type 1 pattern 
are also presented. The 
differences between the 
RSR’ (RSr’) complex in 
the healthy subject and the 
Brugada type 1 pattern 
during positive Ajmaline 
tests are clearly visible. 
 
4. DISCUSSION 
 
The main findings of this retrospective analysis can be summarized as 
follows: 
•  Leads V1 and V2 recorded from the 3
rd i.c. space are more 
sensitive that the standard V1 and V2 leads (4
th i.c. space) for 
detection of type 1 Brugada pattern. 
•  Lead V3, whether recorded from the standard position or one i.c. 
space higher, is of little use for the diagnosis of BS and can 
safely be omitted during Ajmaline test. 
•  A bipolar lead between V2 (positive pole) and either V4 or V5 
(negative pole) is more sensitive than the standard unipolar lead 
V2 for detection of Brugada type 1 pattern.  
 
Our study confirmed previous reports [10,16,20], which demonstrated 
increased sensitivity of the high right precordial leads recorded from one 
or two i.c. spaces higher (3
rd or 2
nd for V1 and V2) compared to the 
standard positions.  
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Meregalli et al. [10] observed type 1 pattern only in leads V1h or V2h (3
rd 
i.c. space) in 21 of 47 positive flecainide tests (45%), whereas in the other 
26 tests it was observed in both conventional and high right precordial 
leads. The clinical value of leads V1h to V3h seems to be similar to 
that of the standard V1 to V3 leads. Miyamoto et al. [12] reported 
that the frequency of cardiac events during follow-up of 19 patients 
with type 1 Brugada pattern observed spontaneously only in V1 and 
V2 leads from 3
rd or 2
nd i.c. space was not significantly different 
from that of 68 patients in whom type 1 pattern was spontaneously 
observed in both the standard (4
th i.c. space) as well as the high V1 
and V2 leads (2/19 (11%) vs 11/68 (16%)). Analysis of our control 
group A suggests that the Brugada pattern does not occurs more 
commonly in leads V1h to V3h than in the standard V1 to V3 leads, 
although the group of 108 healthy subjects is quite small for more 
definite conclusions (in one recent European population-based study 
of 12-lead resting ECGs of 4149 subjects, not a single ECG 
displayed Brugada type 1 pattern) [19].  
 
The diagnostic type 1 Brugada pattern is only rarely observed in lead 
V3 (both in the standard or higher position) during positive Ajmaline 
tests and this lead is not essential for the ECG diagnosis of BS. In the 
absence of ECG recorders with more than 12 simultaneously 
acquired channels, lead V3 can be used instead for monitoring leads 
V1h or V2h during diagnostic Ajmaline testing or therapeutic 
administration of drugs which can provoke Brugada ECG pattern, 
such as NA+ channel blockers (the so-called “acquired Brugada 
syndrome” [18]). 
 
The bipolar precordial leads V2-4 and V2-5  detect  more sensitively the 
appearance of type 1 Brugada pattern during Ajmaline administration than 
the unipolar lead V2 and this pattern in leads V2-4 or V2-5 seems to be quite 
specific for BS since it is rarely observed during negative tests and in 
healthy subjects. However, at this stage the sensitivity and specificity of 
the bipolar precordial leads remain unknown, because these parameters 
can be meaningfully established only in relation to the presence of 
symptoms or arrhythmic events (preferably prospectively evaluated), since 
at present gene mutations cannot be found in the vast majority of the 
patients [22]. Such data were not available in this study. Hence, the 
clinical value of our purely electrocardiographic observations remains to 
be defined.  
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We can only speculate about the mechanisms underlying type 1-like 
pattern in the bipolar precordial leads. The cellular basis of the BS and its 
different ECG patterns is still not clear (for a recent review see [14]). 
According to the “repolarization theory” [1, 8, 9, 15, 17], genetically 
determined or drug-induced reduction of the inward Na+ current leads to 
unopposed transient outward (Ito) current in some epicardial regions of the 
right ventricular outflow tract (RVOT), which causes either delayed 
expression of the action potential (AP) dome and epicardial AP 
prolongation or loss of the dome and AP shortening. The net effect is 
magnification of repolarization dispersion between the RVOT endo- and 
epicardium, and between different RVOT epicardial regions, which is 
potentially arrhythmogenic.  
 
There is also mounting evidence [1, 5, 6, 9]
 for the presence of conduction 
abnormalities in the RVOT and their importance for the genesis of 
ventricular arrhythmias in BS [1, 9] (“the depolarization theory”). The 
presence of late potentials and prolonged filtered QRS duration on signal-
averaged ECG (SAECG) have also been linked to the arrhythmic risk in 
BS [6, 7]. Recently, increased QRS fragmentation was shown to be related 
to the incidence of arrhythmic events in BS [13]. A mechanism explaining 
the Brugada ECG type solely by RVOT conduction delay has also been 
proposed (see Fig. 3 in [11]). 
 
Generally, Brugada type 1 pattern with a negative T wave results from 
early relative (intracellular) positivity of the unaffected zone (RVOT 
endocardium according to the “repolarisation theory” or normally 
activated myocardium outside the RVOT according to the “depolarization 
theory”) and late epicardial relative intracellular positivity in the affected 
RVOT zone due to either prolongation of the epicardial AP or its delayed 
activation. It seems that the type 1-like pattern in leads V2-4 and V2-5 
reflects similar differences between the affected RVOT (predominantly 
epicardial) zones under the V2 electrode and the unaffected left ventricular 
apical epicardial zones under the V4 or V5 electrode (Fig. 6). In cases 
when the type 1 pattern is observed in lead V2h, but not in lead V2, the 
latter typically also demonstrates repolarization changes suggestive of, 
although not diagnostic of BS (type 2 pattern or non-specific ST elevation) 
(e.g. Fig. 2, right panel). It seems that in such cases the electrode at V2h 
directly reflects the affected myocardial zone (in the RVOT), whereas the 
electrode at V2 provides an “oblique view” of this zone in the form of type 
2 pattern (or other kind of ST elevation) in lead V2 and type 1-like pattern 
in lead V2-4 or V2-5.  
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Fig. 6 The figure presents leads 
V2h, V2 and V4 and the subtracted 
bipolar lead V2-4 in order to 
demonstrate a possible mechanism 
of Brugada type 1-like pattern in a 
bipolar precordial lead. A median 
beat created from a 10-second 
recording has been used. The ECG 
has been recorded 6 minutes after 
the start of a positive Ajmaline test 
(development of type 1 ECG in 
leads V1h and V2h) in an 
asymptomatic 35-year-old man. 
 
The bipolar precordial leads may have diagnostic value in patients with 
BS. In the absence of an ECG recorder capable of simultaneous 
acquisition of more than 12 leads, one or more derived precordial bipolar 
leads could considerably enhance the diagnostic power of the standard 12-
lead ECG. With the advent of modern PC-based ECG recorders, one or 
more bipolar precordial leads can easily be derived and displayed online 
simultaneously with the standard precordial leads during diagnostic or 
therapeutic interventions with the help of a simple software upgrade.   
Directly recorded bipolar precordial leads V2-4, V2-5 and possibly others 
may be useful during long-term ambulatory 2 or 3-lead ECG monitoring 
for detection of intermittently appearing Brugada ECG pattern. 
 
5. LIMITATIONS 
 
In some cases, Brugada type 1 pattern is detected more clearly in the lead 
V1 and V2 recorded from the 2
nd instead of the 3
rd i.c. space (unpublished 
observations). The subjects in both control groups were not matched for 
sex and age with those of the study group. However, the average age 
difference of several years between subjects of the study and the 2 control 
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groups is unlikely to account for any ECG differences. The choice of lead 
V2-4 and V2-5 was to a large extent arbitrary. Other bipolar precordial leads 
could possibly provide equally good or better results. A bipolar lead 
between two precordial electrodes does not provide, of course, any 
information that is not contained in the respective unipolar leads; it is 
merely a visually convenient presentation of the difference between the 
two unipolar leads. However, the same is true for the 6 peripheral leads, 
any 2 of which contain all available information (e.g. lead aVR is the 
inverted half-average of lead I and lead II, etc.). Nonetheless the 6-lead 
presentation format of the peripheral ECG is indispensable to clinical 
practice. Finally, for technical reasons the ECG measurement and analysis 
of this study could not be performed in a blinded fashion. 
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